Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook
Key Takeaways from the Pulmonary Fibrosis Pipeline Report
In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis.
DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment.
The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others.
Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others.
Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs
Pulmonary Fibrosis Emerging Drugs Profile
BMS-986278: Bristol-Myers Squibb
BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
AK3280: Ark Biosciences Inc.
AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
LYT-100: PureTech Health
LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
ARO-MMP7: Sarepta Therapeutics
ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
TRK-250: Toray Industries, Inc
TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd.
VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis.
The Pulmonary Fibrosis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment.
Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market
Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs
Pulmonary Fibrosis Companies
Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others.
Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Pulmonary Fibrosis Products have been categorized under various Molecule types such as
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers
Scope of the Pulmonary Fibrosis Pipeline Report
Coverage- Global
Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others.
Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others.
Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Pulmonary Fibrosis: Overview
Therapeutic Assessment
Pulmonary Fibrosis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
BMS-986278: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK3280: Ark Biosciences Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
RSBT 001: RS BioTherapeutics
Drug profiles in the detailed report…..
Inactive Products
Pulmonary Fibrosis Key Companies
Pulmonary Fibrosis Key Products
Pulmonary Fibrosis- Unmet Needs
Pulmonary Fibrosis- Market Drivers and Barriers
Pulmonary Fibrosis- Future Perspectives and Conclusion
Pulmonary Fibrosis Analyst Views
Pulmonary Fibrosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
These 3 Technology Stocks Are Money-Printing Machines
Key Points Broadcom's custom AI chip business continues to power large hyperscaler deployments globally. ServiceNow remains a dominant force in the enterprise workflow automation market. Oracle dominates the enterprise database market and has one of the most secure AI platforms. These 10 stocks could mint the next wave of millionaires › The technology sector has created extraordinary wealth for the shareholders since the dawn of the internet age. While a few of the technology companies have been building critical infrastructure needed to power the digital economy, many others have successfully developed consumer applications that have become indispensable for billions of users. Here are three technology giants that have generated exceptional long-term returns for shareholders and are well worth considering today. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Broadcom Artificial intelligence (AI) infrastructure giant Broadcom (NASDAQ: AVGO) has created an exceptional portfolio of customized semiconductor chips and infrastructure software solutions. Broadcom's financials are impressive. The company raked in $15 billion of revenue in the second quarter of its fiscal 2025 (ended May 4), up 20% year over year. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) reached $10 billion, translating into a 67% margin. The chipmaker produced $6.4 billion in free cash flow during the second quarter and has a strong balance sheet with $9.5 billion in cash. Thanks to its strong cash generation and solid financial position, it has returned an impressive $7 billion to shareholders in the second quarter through dividends and stock buybacks. Broadcom's AI semiconductor business (custom accelerators and AI networking) remains the key growth engine, with revenue rising 46% year over year to $4.4 billion in the second quarter. While custom accelerator revenue was up double-digits, AI networking revenue soared by more than 170% in the second quarter. Management now expects the company's AI semiconductor revenue to grow 60% to $5.1 billion in the third quarter. Unlike Nvidia, which dominates the GPU landscape, Broadcom has become a major provider of custom processors and is currently working with three hyperscalers who are each planning to deploy 1 million AI accelerator clusters by 2027. Besides chips, the company's advances in AI networking (Tomahawk 6 switches) are enabling massive AI clusters in a manner that can lower latency and improve bandwidth, all while reducing power consumption. Broadcom's $61 billion acquisition of VMware, an infrastructure software company, is also proving to be a brilliant move. Broadcom's infrastructure software business now operates at a 93% gross margin and 76% operating margin. Considering Broadcom's cutting-edge AI offerings and robust financials, the stock seems an impressive pick now. ServiceNow ServiceNow (NYSE: NOW) generates substantial revenue by selling enterprise AI and workflow automation solutions through its Now Platform. In the second quarter, the company generated over $3.1 billion in subscription revenue, up 22.5% on a year-over-year basis. With another $102 million earned from professional services and other areas, the company generated more than $3.2 billion in revenue in the second quarter, up 22.5%. Management expects to hit a $15 billion-plus subscription revenue target in 2026. This tech giant has emerged as a significant beneficiary of the increasing adoption of enterprise AI globally. The company's Now Assist offering (a suite of generative AI capabilities integrated into the Now workflow automation platform) is projected to generate $1 billion in annual contracted business by 2026, almost four times higher than $250 million annual contracted value in early 2025. ServiceNow served 528 customers paying above $5 million in annual contracted value, while the number of customers contributing beyond $20 million annually expanded by more than 30% year over year in the second quarter. The company's Now platform boasts a remarkable 98% renewal rate, highlighting the stickiness of its offerings. The enterprise software leader generated $535 million in free cash flows, translating into a 16.5% free-cash-flow margin in the second quarter. The company is committed to returning capital to shareholders, as is evident from $361 million worth of share repurchases in the second quarter. Despite these buybacks, ServiceNow boasts an impressive $10.8 billion in cash and investments at the end of the second quarter. Considering the ServiceNow's many strengths, smart investors should consider at least a small stake in the company. Oracle Oracle (NYSE: ORCL) generates substantial cash flows by developing and selling cloud infrastructure and database software solutions, many of which are powering complex AI workloads. Oracle's database technology works in conjunction with Oracle Cloud Infrastructure (OCI, Oracle's cloud computing platform). It is also compatible with all of the leading cloud platforms, such as Amazon 's AWS, Alphabet 's Google Cloud, and Microsoft 's Azure. Additionally, Oracle Database 23ai enables enterprises to work with their proprietary data and all the popular large language models while maintaining complete security. The company reported $15.9 billion in revenue in the fourth quarter of its fiscal 2025 (ended May 31), up 11% year over year. OCI was a significant growth driver, and saw revenue jump 52% to $3 billion in the fourth quarter. The enterprise technology leader generated $20.8 billion in operating cash flow during fiscal 2025, an increase of 12% year over year. With its backlog growing 41% year over year to $138 billion at the end of fiscal 2025 and further expected to grow 100% by the end of fiscal 2026, Oracle enjoys exceptional revenue visibility. Oracle is also committed to returning capital to shareholders, as is evident from $150 million in share buybacks in the fourth quarter and dividend payments of almost $4.7 billion in fiscal 2025. Management also expects OCI revenue to grow year over year by 70% in fiscal 2026, while total revenue is expected to be at least $67 billion, up 16%. This highlights the company's solid growth prospects in the coming year. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
10 hours ago
- Globe and Mail
The Great Flattening is a quiet evolution as middle managers decline
This is the weekly Work Life newsletter. If you are interested in more careers-related content, sign up to receive it in your inbox. Have you noticed fewer rungs on the corporate ladder lately? For the last few years, as companies invest more capital into artificial intelligence, Big Tech has been cutting layers of management in what's become known as the 'Great Flattening.' Now, new data from Gusto, which provides payroll and HR solutions, shows small and mid-sized businesses (SMBs) are following suit and it's reshaping the way teams are structured, developed and led. From 2022 to 2024, the number of individual contributors per people manager at SMBs has doubled. Back in 2019, managers typically oversaw about three direct reports. Now, that number is about six. Nich Tremper, senior economist at Gusto, says this isn't simply a result of sweeping layoffs, but rather a quiet evolution. 'What seems to be happening is that as folks move on – older folks retire or others shift to new roles – businesses simply aren't backfilling those managerial positions,' he says. The change is largely driven by cost pressures. 'We've seen the average labour cost increase nearly 20 per cent over the last couple of years,' Mr. Tremper says. 'Small businesses don't have a lot of leeway in their budgets, so they're thinking through how best to maximize the productivity of the folks they have on staff. Part of that has come down to reducing management layers.' But the consequences of a leaner org chart extend beyond budgets. What we lose when we flatten While some businesses may appreciate the savings and agility that come with fewer layers of hierarchy, Mr. Tremper cautions against seeing it as a purely positive shift. 'These middle managers are really important for organizations,' he says. 'You have strategic decisions and guidance coming from the highest level of management, but it's individual managers who are turning those directions into actionable steps.' In other words, fewer managers may mean faster decision-making in the short term, but also the risk of teams lacking mentorship, development and day-to-day leadership. 'Highly productive sectors tend to maintain more managers with smaller teams,' Mr. Tremper says. 'It suggests that first-line managers play a critical role in scaling their expertise, developing their teams and ultimately boosting productivity.' Even in lower-productivity industries, measured by total output per hour worked, Gusto found that businesses with a higher share of managers tend to outperform their peers. Managers are opting out, too Not only are businesses hiring fewer managers but existing ones are leaving. In late 2024, Gusto found that the quit rate among managers was about 10 per cent higher than it was in January 2022, when it was more of an employee-driven labour market. 'Quit rates are often viewed as a sign of labour market confidence,' says Mr. Tremper. 'If managers are leaving, it could mean they believe they can find more meaningful work elsewhere. They might be looking to lead teams at other companies or return to being high-performing individual contributors.' Some may even be taking the opportunity to pivot entirely. 'For folks who are maybe no longer managers, this could be a chance to ask: What path do I really want? Do I want to be an individual expert? Or maybe this is the time to start my own business or consulting practice.' Flattening with intention The Great Flattening may seem like a cost-saving trend but it comes with trade-offs. While it can boost short-term agility, businesses that cut too deeply may sacrifice long-term development and stability. Mr. Tremper says business leaders should think carefully about what they're giving up. 'When I think of the most effective managers I've had, they've cared deeply about my professional development. They created opportunities for me to grow beyond my current skill set,' he says. Small businesses especially, he adds, rely on strong teams and strong teams often rely on great managers. 11 per cent According to new data from book summary app company Headway, while many workers are enjoying a slow summer season, more than one in 10 say their workload has increased. Read more Experts say rebranding yourself is about more than a job title or what you wear. It's important to be authentic about how you're changing personally and professionally and share that story over time. On a more tactical level, you can also get new headshots, work with a coach and spend time connecting intentionally with your current network and new peers in your industry. Read more 'Being punctual is a form of non-verbal communication. By showing up on time, you're non-verbally telling that person you care enough about their time and the task at hand. It's a representation of your work ethic and competency,' says etiquette trainer Mariah Grumet Humbert. This article looks at how punctuality norms have evolved over time and how being chronically late can impact your personal brand at work and in life. Read more Robert Half research reveals that Gen Z and professionals in tech are the most likely to search for a new job in the next six months. For the first time since the staffing firm began tracking worker sentiment, the research shows better benefits and perks rank as the highest motivator for workers exploring new roles. Read more
Globe and Mail
11 hours ago
- Globe and Mail
2 Surefire Stocks to Invest $1,000 in for the Long Haul
Key Points Alphabet can overcome an antitrust challenge thanks to strong growth prospects and substantial cash flow. Intuitive Surgical leads its niche of the medical device market and still has ample whitespace ahead. 10 stocks we like better than Alphabet › Investing in stocks is both accessible to the general public and likely to yield strong returns over the long term. That's what makes it one of the best ways to increase your wealth. However, putting your money in the right stocks is crucial. Some companies may turn out to be terrible investments, as they significantly lag behind the market and may even cease to exist. Investors can avoid that fate by investing in ETFs that track major indexes or by selecting stocks that have the potential to outperform broader equities over extended periods. These are typically well-established, highly profitable companies with solid businesses, excellent prospects, and strong competitive edges. Here are two brilliant examples: Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), and Intuitive Surgical (NASDAQ: ISRG). Here's why putting $1,000 into either of those stocks would be a great move. 1. Alphabet Alphabet has been one of the more undervalued among the trillion-dollar tech leaders of late. In fairness, that's because it faces some potential headwinds related to antitrust lawsuits in the U.S. Regulators want the company to relinquish its Chrome browser, a key component of its advertising business. While that's worth keeping an eye on, Alphabet continues to impress with its financial results. The company's second-quarter earnings were no different. The tech giant grew its revenue by 14% year over year to $96.4 billion, while its net earnings per share (EPS) of $2.31 were up 22.2% compared to the year-ago period. Some of Alphabet's current growth drivers, including cloud computing and artificial intelligence (AI), should remain so for many years to come. The company pointed out that its cloud division, Google Cloud, now has a revenue run rate of more than $50 billion. Though Alphabet's advertising business remains its main cash cow, cloud and AI could take over in the next decade. Investors should be excited about that since it will mean that the company will become far less reliant on its advertising business, which would take the biggest hit if Alphabet loses Chrome. So, the more diversified the business becomes, the less of a risk this potential worst-case scenario of losing Chrome is. Furthermore, Alphabet is exploring other potential opportunities, including streaming through YouTube, a leader in that niche, and self-driving cars through its subsidiary, Waymo. Lastly, Alphabet has a strong competitive edge from multiple sources, including Google's network effect and strong brand name, as well as the switching costs associated with its cloud solutions. Alphabet is firing on all cylinders, and the company's long-term prospects remain bright. Even if regulators in the U.S. succeed in forcing the company to relinquish its Chrome browser, Alphabet should recover due to having multiple lucrative opportunities and significant amounts of free cash flow -- to the tune of $5.3 billion as of the end of the second quarter. That's significantly lower than the $13.5 billion it had as of the end of Q2 2024, but that's partly because Alphabet is reinvesting substantial amounts, including a projected $85 billion this year, into capital expenditures to support various growth opportunities. This investment could pay for itself several times over in the long run as the company makes further progress in cloud, AI, and other areas. Alphabet remains well-positioned to outperform the market over the next decade. Investors can get five of the company's shares for $1,000. 2. Intuitive Surgical Intuitive Surgical, the leader in the robotic-assisted surgery (RAS) market, has struggled this year. Trump's aggressive tariffs could take a bite out of the company's earnings, which is why many investors are choosing to stay away from the stock. However, the medical device specialist's outlook is still strong, at least for investors willing to be patient. For one, Intuitive Surgical continues to record excellent financial results. The company's second-quarter revenue was $2.44 billion, 21% higher than the year-ago period, thanks to a 17% year-over-year increase in the number of procedures performed with its crown jewel, the Da Vinci System. Intuitive Surgical's adjusted EPS came in at $2.19, 23% higher than Q2 2024. The company has had little competition in the RAS field, and although that's about to change, several factors should allow it to perform well over the next decade. First, it will be challenging for newcomers to catch up, as Intuitive Surgical has been earning indications for the Da Vinci System for years. It is approved for use in general surgeries, bariatric procedures, urologic procedures, gynecologic procedures, and more. Second, since the Da Vinci System is expensive and requires a learning curve, after putting considerable time and money into acquiring one and training medical staff on it, healthcare facilities will need a lot of convincing to switch to a competitor. In other words, Intuitive Surgical benefits from high switching costs. Third, the company is an innovator. It earned clearance for the fifth generation of its crown jewel last year and will undoubtedly continue to improve the device. Lastly, there is significant whitespace in the RAS market. Intuitive Surgical will benefit from the world's aging population, as older individuals are more likely to require many of the procedures performed with its Da Vinci system. Even with the current volume of surgeries, RAS procedures have captured only 5% of those eligible for robotic surgery. That points to a massive opportunity, and as a leader in the market, Intuitive Surgical should benefit. The stock may be down this year, but it could deliver superior returns over the long run. With $1,000, investors can purchase two shares. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
